PET in T-cell lymphoma

Current Hematologic Malignancy Reports

Volumn 6, Issue 4, 2011, Pages 241-244

  Zinzani, Pier Luigi ^a  

^a Istituto di Ematologia 'L e A Seràgnoli'   (Italy)

Author keywords

CT scan; Cutaneous T cell lymphoma; Peripheral T cell lymphoma; PET scan; PET CT; Positron emission tomography; Prognosis; Staging; SUV; T cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOISOTOPE;

ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER STAGING; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, T-CELL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 81355160675     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0098-6     Document Type: Article

References (32)

1. PP Carbone HS Kaplan K Musshoff, et al. 1971 Report of the committee on Hodgkin's disease staging classification Cancer Res 31 1860 1 5121694 1:STN:280:DyaE38%2Fks1yitw%3D%3D
2. G Jerusalem V Warland F Najjar, et al. 1999 Whole-body 18 F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma Nucl Med Commun 20 13 20 9949408 10.1097/00006231-199901000-00004 1:STN:280:DyaK1M7jsVGltQ%3D%3D (Pubitemid 29084592)
3. I Buchmann M Reinhardt K Elsner, et al. 2001 2-(fluorine- 18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial Cancer 91 889 99 11251940 10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5 1:STN:280:DC%2BD3M7pvVykuw%3D%3D (Pubitemid 32201160)
4. B Rodriguez-Vigil N Gomez-Leon I Pinilla, et al. 2006 PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT J Nucl Med 47 1643 8 17015900 (Pubitemid 47545030)
5. TC Kwee RM Kwee RA Nievelstein 2008 Imaging in stagin of malignant lymphoma: a systematic review Blood 111 504 16 17916746 10.1182/blood-2007-07- 101899 1:CAS:528:DC%2BD1cXns1Chug%3D%3D
6. G Jerusalem Y Beguin F Najjar, et al. 2001 Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL) Ann. Oncol. 12 825 30 11484959 10.1023/A: 1011169332265 1:STN:280:DC%2BD38%2FislSrtA%3D%3D (Pubitemid 32655093)
7. M Bangerter F Moog I Buchmann, et al. 1998 Whole-body 2- [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease Ann. Oncol. 9 1117 22 9834825 10.1023/A:1008486928190 1:STN:280:DyaK1M%2FltFyqsg%3D%3D (Pubitemid 28518151)
8. G Jerusalem Y Beguin MF Fassotte, et al. 2001 Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease Haematologica 86 266 73 11255273 1:STN:280:DC%2BD3M3lsFShuw%3D%3D (Pubitemid 32291064)
9. MR Weihrauch D Re S Bischoff, et al. 2002 Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease Ann. Hematol. 81 20 5 11807631 10.1007/s00277-001-0390-y 1:CAS:528:DC%2BD38XjsVWrsg%3D%3D (Pubitemid 36075491)
10. R Naumann B Beuthien-Baumann A Reiss, et al. 2004 Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma Br J Cancer 90 620 5 14760374 10.1038/sj.bjc.6601561 1:STN:280:DC%2BD2c%2FlvVCnsw%3D%3D (Pubitemid 38297200)
11. JS Newman JR Francis MS Kaminski, et al. 1994 Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-Dglucose: correlation with CT Radiology 190 111 6 8259386 1:STN:280:DyaK2c%2Fot1WmsA%3D%3D
12. R Thill J Neuerburg U Fabry, et al. 1997 Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma Nuklearmedizin 36 234 9 9441282 1:STN:280:DyaK1c%2Fls1ajtg%3D%3D (Pubitemid 27489459)
13. R Elstrom L Guan G Baker, et al. 2003 Utility of FDG-PET scanning in lymphoma by WHO classification Blood 101 3875 6 12531812 10.1182/blood-2002-09- 2778 1:CAS:528:DC%2BD3sXktVGntLk%3D (Pubitemid 36857861)
14. N Tsukamoto M Kojima M Hasegawa, et al. 2007 The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) and a comparison of 18FFDG- PET with 67gallium scintigraphy in the evaluation of lymphoma. Relation to histologic subtypes based on the World Health Organization classification Cancer 110 652 9 17582800 10.1002/cncr.22807 (Pubitemid 47106156)
15. • Khong P-L, Pang CBY, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613-21. This article presents interesting data on the role of PET scans in mature T-cell and NK-cell malignancies.
16. • Berk V, Yildiz R, Akdemir UO, et al. Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules. Utility of 18F-FDG PET in staging. Clin Nucl Med. 2008;33:365-6. This article presents an evaluation of PET scans in rating T-cell disorders. (Pubitemid 351589538)
17. S Kako K Izutsu Y Ota, et al. 2007 FDG PET in T-cell and NK-cell neoplasms Ann. Oncol. 18 1685 90 17716987 10.1093/annonc/mdm265 1:STN:280:DC%2BD2srmslCgtg%3D%3D (Pubitemid 47506256)
18. C Suh Y-K Kang J-L Roh, et al. 2008 Prognostic value of tumor 18F-FDG uptake in patients with untreated exranodal natural killer/T-cell lymphomas of the head and neck J Nucl Med 49 1783 9 18927319 10.2967/jnumed.108.053355
19. SM Horwitz F Foss S Goldfarb, et al. 2006 FDG-PET scans as a staging study for T-cell lymphomas: high rates of positivity do not result in frequent changes in stage Blood 108 679a abstract 2399
20. D Karantanis RM Subramanium PJ Peller, et al. 2008 The value of [18F] fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma Clin Lymphoma Myeloma 8 94 9 18501102 10.3816/CLM.2008.n.010 (Pubitemid 351775766)
21. M Hadithi M Mallant J Oudejans, et al. 2006 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease J Nucl Med 47 1622 7 17015897 (Pubitemid 47545027)
22. J Okada H Oonishi K Yoshikawa, et al. 1994 FDG-PET for predicting the prognosis of malignant lymphoma Ann Nucl Med 8 187 91 7811561 10.1007/BF03164996 1:STN:280:DyaK2M7htVKlsQ%3D%3D (Pubitemid 24290785)
23. N Watanabe J Murakami K Kameda, et al. 2008 F-18 FDGPET imaging in adult T-cell leukemia lymphoma Clin Nucl Med 33 423 5 18496454 10.1097/RLU. 0b013e318170826b
24. M Shapiro M Yun JM Junkins-Hopkins, et al. 2002 Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas J Amer Acad Dermatol 47 623 8 10.1067/mjd.2002.124076
25. M Hoffmann H Vogelsang K Kletter, et al. 2003 18F-fluorodeoxy- glucose positron emission tomography (18FFDG- PET) for assessment of enteropathy-type T cell lymphoma Gut 52 347 51 12584214 10.1136/gut.52.3.347 1:STN:280: DC%2BD3s%2FpsFyjsw%3D%3D (Pubitemid 36250052)
26. • Kuo PH, McClennan BL, Carlson K, et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol. 2008;10:74-81. This article compares PET and CT scans in the evaluation of patients with cutaneous T-cell lymphoma.
27. EY Tsai A Taur L Espinosa, et al. 2006 Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography Arch. Dermatol. 142 577 84 16702495 10.1001/archderm.142.5.577 (Pubitemid 43727548)
28. R Kumar Y Xiu HM Zhuang, et al. 2006 18F-fluorodeoxyglucose- positron emission tomography in evaluation of primary cutaneous lymphoma Br. J. Dermatol. 155 357 63 16882175 10.1111/j.1365-2133.2006.07367.x 1:STN:280: DC%2BD28vlvVOjsg%3D%3D (Pubitemid 44050570)
29. PH Kuo KR Carlson I Christensen, et al. 2008 FDG-PET/CT for the evaluation of response to therapy of cutaneous Tcell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial Mol Imaging Biol 10 306 14 18665425 10.1007/s11307-008-0161-4
30. A Gallamini L Rigaci F Merli, et al. 2006 Predictive value of positron emission tomography performer after two coureses of standard therapy on treatment out come in advanced stage Hodgkin's disease Haematologica 91 475 81 16585014
31. PL Zinzani M Tani S Fanti, et al. 2006 Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann. Oncol. 17 1296 300 16766583 10.1093/annonc/mdl122 1:STN:280: DC%2BD28rivFSrtQ%3D%3D (Pubitemid 44288221)
32. A Gallamini M Hutchings L Rigacci, et al. 2007 Early interim 2-[18F] fluoro-2-D-glucose positron emission tomography is prognostically superior to International prognostic score in advanced stage Hodgkin's lymphoma: a report from a joint Italian-Danish study J. Clin. Oncol. 25 3746 52 17646666 10.1200/JCO.2007.11.6525 1:CAS:528:DC%2BD2sXhtVeqt7fE (Pubitemid 47372616)